Paris hospitals group, AP-HP, and Biocitech sign cooperation agreement
Partnership aims to speed development of early stage healthcare companies and increase opportunities for those with innovative projects from AP-HP or Biocitech
Biocitech and AP-HP announced that they have signed a cooperation agreement. The agreement was signed by Mireille Faugere, managing director of AP-HP and Jean-Francois Boussard, Biocitech president, at the ninth annual APinnov technology transfer conference in Paris.
Together, the two partners intend to accelerate the creation and scientific development of early-stage life sciences enterprises. Those with projects to propose from AP-HP will be able to use premises at Biocitech, near central Paris, on favorable terms while Biocitech residents will have special access to technological innovations originating in AP-HP. Agreements will cover areas such as technology transfer, co-development or clinical development.
There will be a joint development and oversight committee with representatives from OTTLIV, the technology transfer arm of AP-HP, and from Biocitech. They will be responsible for ensuring the smooth running of joint actions. The committee will take decisions on companies moving into Biocitech with technology originating from AP-HP, on Biocitech residents wanting to access AP-HOP technology and on requests from Biocitech residents wishing to have their medicines evaluated in clinical trials at AP-HP.
Other news from the department business & finance
